Alpha Synucleinopathy Associated Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Alpha-synucleinopathy-associated neurons are neurons that accumulate pathological alpha-synuclein (α-Syn) aggregates in the form of Lewy bodies and Lewy neurites. These proteinaceous inclusions characterize a group of neurodegenerative diseases collectively termed synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA)[1][2]. Understanding which neuronal populations are vulnerable to alpha-synuclein pathology, and why, is critical for developing disease-modifying therapies.
The most prominently affected region in PD[3]:
Early involvement in disease progression:
Pathological staging reveals early involvement:
The pathological process involves protein misfolding and aggregation[4]:
| Stage | Species | Characteristics | Toxicity |
|---|---|---|---|
| 1 | Monomeric α-Syn | Normal neuronal function | None |
| 2 | Oligomeric α-Syn | Soluble aggregates | High |
| 3 | Protofibrils | Intermediate aggregates | Moderate |
| 4 | Fibrils | Lewy body components | Low (inert) |
Different α-Syn strains:
| Gene | Effect on α-Syn Pathology |
|---|---|
| SNCA multiplication | Increased expression, earlier onset |
| GBA1 mutations | Higher burden, faster progression |
| LRRK2 mutations | Variable effects |
| PARK2/PARKIN | Less Lewy bodies (paradox) |
Mitochondrial dysfunction:
ER stress:
Oxidative stress:
Membrane pore formation:
Transport disruption:
| Strategy | Example | Mechanism | Status |
|---|---|---|---|
| Aggregation inhibitors | Anle138b | Block fibril formation | Preclinical |
| Immunotherapy | Prasinezumab | Clear α-Syn aggregates | Phase 2 |
| Gene therapy | AAV-AADC | Enhance dopamine | Clinical |
| Cell replacement | iPSC-dopamine | Neuron transplantation | Preclinical |
The progression of α-Syn pathology follows a characteristic pattern[5]:
| Stage | Affected Regions | Clinical Correlation |
|---|---|---|
| 1 | DMV, LC | Preclinical |
| 2 | Lower brainstem | Non-motor symptoms |
| 3 | SNc, amygdala | Motor symptoms |
| 4 | Temporal cortex | Cognitive changes |
| 5-6 | Neocortex | Dementia |
Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997
Lashuel HA, et al. The many faces of alpha-synuclein. J Mol Biol. 2013
Alpha Synucleinopathy Associated Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Alpha Synucleinopathy Associated Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Spillantini MG, et al. (1997). Alpha-synuclein in Lewy bodies. Nature, 388(6645), 839-840. ↩︎
Braak H, et al. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging, 24(2), 197-211. ↩︎
Kalia LV, Lang AE. (2015). Parkinson's disease. Lancet, 386(9996), 896-912. ↩︎
Lashuel HA, et al. (2013). The many faces of alpha-synuclein: From structure and toxicity to therapeutic targeting. J Mol Biol, 425(24), 3893-3908. ↩︎
Del Tredici K, Braak H. (2016). Review: Sporadic Parkinson's disease: Development and distribution of alpha-synuclein pathology. Neuropathology and Applied Neurobiology, 42(1), 33-50. ↩︎